Blood test may guide ovarian cancer maintenance therapy
NCT ID NCT05027828
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a blood test for circulating tumor DNA (ctDNA) can help predict how well PARP inhibitor maintenance therapy works in women with high-grade serous ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, during targeted therapy, and at disease progression. The goal is to see if ctDNA levels can guide treatment decisions and detect recurrence early. The study plans to enroll 100 participants who are newly diagnosed and receiving first-line treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a blood test that helps doctors choose the right maintenance therapy for ovarian cancer and catch recurrence earlier.
What could go wrong
This is an observational study, not a treatment trial. It is still recruiting and results may not change practice immediately. The approach may not prove reliable for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••